MorphoSys AG MOR-DE:XETRA

*Data is delayed | Exchange | EUR
Last | 2:32 PM CEST
67.75quote price arrow down-0.10 (-0.15%)
Volume
9,768
52 week range
14.52 - 68.20
Loading...
  • Open67.75
  • Day High67.90
  • Day Low67.45
  • Prev Close67.85
  • 52 Week High68.20
  • 52 Week High Date05/14/24
  • 52 Week Low14.52
  • 52 Week Low Date11/21/23

Key Stats

  • Market Cap2,719.19M
  • Shares Out37.66M
  • 10 Day Average Volume106,547.78
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change99.26

KEY STATS

  • Open67.75
  • Day High67.90
  • Day Low67.45
  • Prev Close67.85
  • 52 Week High68.20
  • 52 Week High Date05/14/24
  • 52 Week Low14.52
  • 52 Week Low Date11/21/23
  • Market Cap2,719.19M
  • Shares Out37.66M
  • 10 Day Average Volume106,547.78
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change99.26

RATIOS/PROFITABILITY

  • EPS (TTM)-12.54
  • P/E (TTM)-5.40
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On MorphoSys AG

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is...
Lucinda Crabtree Ph.D.
Chief Financial Officer, Member of the Executive Committee
Address
Semmelweisstr. 7
Planegg
82152
Germany